A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 483 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Telehealth Can Save People with Cancer Time, Travel, and Money February 16, 2023 Opinion: ‘The UK must be more ambitious than just clearing the... May 24, 2021 Learning From Being Lost July 14, 2021 Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... October 18, 2022 Load more HOT NEWS A winding journey into the world of children’s and young people’s... Cancer and Climate Change: The Health Threats of Unnatural Disasters Waiting for Insurance to Cover Her Mammogram Could Have Cost This... ¿Las píldoras anticonceptivas afectan mi riesgo de cáncer?
